{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"87","upperLimit":"238","value":"106"}]}],"title":"Discontinuation (or never started) prednisone"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"266","upperLimit":"405","value":"349"}]}],"title":"Discontinuation of systemic immunosuppression (including calcineurin inhibitors)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Measure the number of days to discontinuation of systemic immunosuppression (both including and excluding calcineurin inhibitors) in pediatric recipients of CD45RA+ T cell-depleted PBSCT. Possible outcomes range from no systemic immunosuppression (best outcome) to 5 years on immunosuppression (poor outcome)","dispersionType":"Inter-Quartile Range","groups":[{"description":"All participants in single arm study of CD45RA+ T cell depletion PBSC transplant and Methotrexate and tacrolimus for GVHD prophylaxis that were alive at D100","id":"OG000","title":"Overall Study Patients Alive at D100"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"5 years post transplant","title":"Time to Discontinuation of Systemic Immunosuppression","type":"PRIMARY","unitOfMeasure":"Days"}